Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539124 | 0.74 | CYP3A4 (0.46) | GAAMAPTALDH1A1POLBTSHR | |
| SCHEMBL7566631 | 0.74 | FSCN1 (0.45) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14000126 | 0.70 | TSHR (0.37) | GAAMAPTALDH1A1POLBTSHR | |
| SCHEMBL6098011 | 0.69 | F2 (0.43) | GAAMAPTALDH1A1POLBTSHR | |
| SCHEMBL1027697 | 0.68 | MEN1 (0.46) | GAAMAPTALDH1A1POLBTSHR | |
| SCHEMBL11695239 | 0.68 | CYP3A4 (0.43) | GAAPOLBTSHRMEN1KMT2A | |
| SCHEMBL10067205 | 0.67 | TSHR (0.49) | GAAMAPTALDH1A1POLBTSHR | |
| SCHEMBL28026747 | 0.66 | CYP3A4 (0.42) | GAAMAPTPOLBTSHRMEN1 | |
| SCHEMBL2331714 | 0.66 | MAPT (0.41) | GAAMAPTALDH1A1POLBTSHR | |
| SCHEMBL28300026 | 0.66 | MEN1 (0.44) | GAAALDH1A1POLBTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135492-B2 | Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | WYETH | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | FFAR4, FFAR1, MSR1 | GAA 4801/4885MAPT 4387/4885ALDH1A1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.